Anti - VEGF treatment

Candidates for anti-VEGF treatment are typically individuals diagnosed with the above-mentioned eye conditions, where abnormal blood vessel growth contributes to vision loss or impairment. The suitability of a patient for anti-VEGF treatment is determined based on factors such as the severity of the condition, the extent of abnormal blood vessel growth, and the overall health of the eye.

Preparation for anti-VEGF treatment involves undergoing a comprehensive eye examination, including visual acuity testing, optical coherence tomography (OCT), and fluorescein angiography to assess the extent of the condition and determine the treatment plan. Prior to treatment, patients may need to discontinue certain medications or undergo specific tests as advised by their ophthalmologist.

Anti-VEGF treatment involves the administration of medications such as ranibizumab, bevacizumab, or aflibercept through injections directly into the eye. These medications work by blocking the activity of VEGF, which helps reduce abnormal blood vessel growth, leakage, and inflammation in the retina, thereby preserving vision and preventing further damage. Treatment is typically administered at regular intervals determined by the ophthalmologist based on the patient's response to therapy and the severity of the condition.

The results of anti-VEGF treatment can vary depending on factors such as the specific eye condition being treated, the extent of damage, and the individual patient's response to therapy. Many patients experience significant improvement in vision and stabilization of the condition following anti-VEGF treatment, with some achieving partial or complete resolution of symptoms.

Patients undergoing anti-VEGF treatment should be closely monitored by their ophthalmologist for any adverse effects or complications, such as intraocular inflammation, elevated intraocular pressure, or retinal detachment. Patients need to attend all scheduled follow-up appointments to assess treatment response, monitor eye health, and adjust the treatment plan as necessary. Patients should also be aware of the potential risks and benefits of anti-VEGF treatment and discuss any concerns with their ophthalmologist before initiating therapy.